Topoisomerase Inhibitors of Marine Origin and Their Potential Use as Anticancer Agents

2005 ◽  
pp. 89-108 ◽  
Author(s):  
Nathalie Dias ◽  
Hervé Vezin ◽  
Amélie Lansiaux ◽  
Christian Bailly
Keyword(s):  
Anticancer Agents ◽  
Topoisomerase Inhibitors ◽  
Marine Origin ◽  
Potential Use

scholarly journals Secondary Metabolites from Marine Sources with Potential Use as Leads for Anticancer Applications

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4292
Author(s):  
Ana C. S. Veríssimo ◽  
Mário Pacheco ◽  
Artur M. S. Silva ◽  
Diana C. G. A. Pinto
Keyword(s):  
Bioactive Compounds ◽  
Anticancer Agents ◽  
Sea Urchins ◽  
Therapeutic Agents ◽  
Marine Organisms ◽  
Marine Origin ◽  
Anticancer Properties ◽  
The Past ◽  
New Compounds ◽  
Potential Use

The development of novel anticancer agents is essential to finding new ways to treat this disease, one of the deadliest diseases. Some marine organisms have proved to be important producers of chemically active compounds with valuable bioactive properties, including anticancer. Thus, the ocean has proved to be a huge source of bioactive compounds, making the discovery and study of these compounds a growing area. In the last few years, several compounds of marine origin, which include algae, corals, and sea urchins, have been isolated, studied, and demonstrated to possess anticancer properties. These compounds, mainly from securamines and sterols families, have been tested for cytotoxic/antiproliferative activity in different cell lines. Bioactive compounds isolated from marine organisms in the past 5 years that have shown anticancer activity, emphasizing the ones that showed the highest cytotoxic activity, such as securamines H and I, cholest-3β,5α,6β-triol, (E)-24-methylcholest-22-ene-3β,5α,6β-triol, 24-methylenecholesta-3β,5α,6β-triol, and 24-methylcholesta-3β,5α,6β-triol, will be discussed in this review. These studies reveal the possibility of new compounds of marine origin being used as new therapeutic agents or as a source of inspiration to develop new therapeutic agents.

scholarly journals Topoisomerases as anticancer targets

2018 ◽  
Vol 475 (2) ◽  
pp. 373-398 ◽  
Author(s):  
Justine L. Delgado ◽  
Chao-Ming Hsieh ◽  
Nei-Li Chan ◽  
Hiroshi Hiasa
Keyword(s):  
Anticancer Drugs ◽  
Anticancer Agents ◽  
Topoisomerase Ii ◽  
Therapeutic Targets ◽  
Strand Break ◽  
Cancer Type ◽  
Topoisomerase Inhibitors ◽  
Topoisomerase Ii Poisons ◽  
Topoisomerase Poisons ◽  
Replication Fork Arrest

Many cancer type-specific anticancer agents have been developed and significant advances have been made toward precision medicine in cancer treatment. However, traditional or nonspecific anticancer drugs are still important for the treatment of many cancer patients whose cancers either do not respond to or have developed resistance to cancer-specific anticancer agents. DNA topoisomerases, especially type IIA topoisomerases, are proved therapeutic targets of anticancer and antibacterial drugs. Clinically successful topoisomerase-targeting anticancer drugs act through topoisomerase poisoning, which leads to replication fork arrest and double-strand break formation. Unfortunately, this unique mode of action is associated with the development of secondary cancers and cardiotoxicity. Structures of topoisomerase–drug–DNA ternary complexes have revealed the exact binding sites and mechanisms of topoisomerase poisons. Recent advances in the field have suggested a possibility of designing isoform-specific human topoisomerase II poisons, which may be developed as safer anticancer drugs. It may also be possible to design catalytic inhibitors of topoisomerases by targeting certain inactive conformations of these enzymes. Furthermore, identification of various new bacterial topoisomerase inhibitors and regulatory proteins may inspire the discovery of novel human topoisomerase inhibitors. Thus, topoisomerases remain as important therapeutic targets of anticancer agents.

Thiazole in the targeted anticancer drug discovery

2019 ◽  
Vol 11 (15) ◽  
pp. 1929-1952 ◽  
Author(s):  
Adileh Ayati ◽  
Saeed Emami ◽  
Setareh Moghimi ◽  
Alireza Foroumadi
Keyword(s):  
Drug Discovery ◽  
Cancer Therapy ◽  
Mechanism Of Action ◽  
Anticancer Agents ◽  
Causes Of Death ◽  
Structure Activity ◽  
The World ◽  
Cancerous Cells ◽  
Potential Use ◽  
Anticancer Drug Discovery

Cancer is known as one of the main causes of death in the world; and many compounds have been synthesized to date with potential use in cancer therapy. Thiazole is a versatile heterocycle, found in the structure of many drugs in use as well as anticancer agents. This review provides an overview of recent advances in thiazole-bearing compounds as anticancer agents with particular emphasis on their mechanism of action in cancerous cells. Chemical designs, structure–activity relationships and relevant preclinical properties have been comprehensively described.

Potential use of nuisance cyanobacteria as a source of anticancer agents

2021 ◽  
pp. 203-231
Author(s):  
Hojun Lee ◽  
Stephen Depuydt ◽  
Soyeon Choi ◽  
Geonhee Kim ◽  
Youngdo Kim ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Potential Use

scholarly journals Several Alkaloids Derived from Plants and Their Underlying Molecular Mechanisms of Action in the Fight Against Cancer

2016 ◽  
Vol 35 (2) ◽  
pp. 83
Author(s):  
Siribhorn Madla ◽  
Potchanapond Graidist
Keyword(s):  
Natural Products ◽  
Anticancer Agents ◽  
Animal Studies ◽  
Molecular Mechanisms ◽  
Causes Of Death ◽  
Short Review ◽  
Mechanisms Of Action ◽  
Apoptosis Pathways ◽  
Potential Use

Multidrug resistance is one of the major obstacles to successful cancer chemotherapy, which causes cancer to remain one of the leading causes of death worldwide. Therefore, the use of natural products for cancer prevention and therapy has been continuously investigated and developed for decades. Alkaloids are one of the important compounds derived from natural products that have been extensively studied for their potential use as cancer chemopreventive and chemotherapeutic drugs in both in vitro and animal studies. This short review intends to present the molecular mechanisms of action of alkaloids on stimulation and inhibition some signaling molecules involved in cell proliferation, differentiation, angiogenesis, metastasis and apoptosis pathways of cancer cells. The understanding of the molecular mechanisms of alkaloids against cancer will provide clues towards a diagnostic, prevention and therapeutic applications. Based on the information provided in this article, alkaloids show remarkable potential as anticancer agents. However, more research and clinical trials are crucial before applying any of these alkaloids as new medicine to treat cancer patients. 

Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents

2016 ◽  
Vol 16 (15) ◽  
pp. 1219-1229 ◽  
Author(s):  
Muthu K. Kathiravan ◽  
Anuj N. Kale ◽  
Shrikant Nilewar
Keyword(s):  
Anticancer Agents ◽  
Topoisomerase Inhibitors

A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade

2019 ◽  
Vol 171 ◽  
pp. 129-168 ◽  
Author(s):  
Xiaoxia Liang ◽  
Qiang Wu ◽  
Shangxian Luan ◽  
Zhongqiong Yin ◽  
Changliang He ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Topoisomerase Inhibitors ◽  
Comprehensive Review ◽  
The Past

scholarly journals Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2863 ◽  
Author(s):  
Caroline Molinaro ◽  
Alain Martoriati ◽  
Lydie Pelinski ◽  
Katia Cailliau
Keyword(s):  
Anticancer Agents ◽  
Copper Complexes ◽  
Molecular Mechanisms ◽  
Cell Cycle Checkpoints ◽  
Topoisomerase Inhibitors ◽  
Dna Breaks ◽  
Cancer Chemotherapeutics ◽  
Highly Active ◽  
Copper Compounds ◽  
Synthetic View

Organometallics, such as copper compounds, are cancer chemotherapeutics used alone or in combination with other drugs. One small group of copper complexes exerts an effective inhibitory action on topoisomerases, which participate in the regulation of DNA topology. Copper complexes inhibitors of topoisomerases 1 and 2 work by different molecular mechanisms, analyzed herein. They allow genesis of DNA breaks after the formation of a ternary complex, or act in a catalytic mode, often display DNA intercalative properties and ROS production, and sometimes display dual effects. These amplified actions have repercussions on the cell cycle checkpoints and death effectors. Copper complexes of topoisomerase inhibitors are analyzed in a broader synthetic view and in the context of cancer cell mutations. Finally, new emerging treatment aspects are depicted to encourage the expansion of this family of highly active anticancer drugs and to expend their use in clinical trials and future cancer therapy.

Topoisomerase II Inhibitors in Cancer Treatment

2011 ◽  
Vol 3 (4) ◽  
pp. 1173-1181
Author(s):  
Devendra Singh Thakur
Keyword(s):  
Anticancer Agents ◽  
Topoisomerase Ii ◽  
Double Helix ◽  
Clinical Use ◽  
Topoisomerase Inhibitors ◽  
Dna Double Strand Breaks ◽  
Metabolic Processes ◽  
Strand Breaks ◽  
Cellular Target ◽  
Dna Double Helix

Topoisomerase II constitutes a family of nuclear enzymes essential to all living cells. These enzymes are capable of transferring one DNA double helix through a transient break in another DNA double helix. Type II topoisomerases play important roles in DNA metabolic processes, in which they are involved in DNA replication, transcription, chromosome condensation and de-condensation. Topoisomerase II is also the cellular target for a number of widely used anticancer agents currently in clinical use, such as the anthracyclines (daunorubicin and doxorubicin), the epipodophyllotoxins (etoposide and teniposide), and the aminoacridines. These agents stimulate the topoisomerase II-cleavable complex, which is a transient configuration of topoisomerase II on DNA in which topoisomerase II is covalently attached to DNA. This causes the accumulation of cytotoxic nonreversible DNA double-strand breaks generated by the processing of such complexes by DNA metabolic processes. As of present, the clinical use of catalytic topoisomerase inhibitors as antineoplastic agents is limited to aclarubicin and MST-16. Both of these compounds are preferentially active toward hematological malignancies and show limited activity toward solid tumors. This review explains the role of topoisomerase inhibitors in cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document